Insulin potentiates the anticonvulsive activity of phenytoin against maximal electroshock-induced seizures in mice

被引:0
作者
Alaraj, M. [1 ,2 ]
Saadh, M. J. [1 ]
Alafnan, A. [3 ]
机构
[1] Middle East Univ, Fac Pharm, Amman, Jordan
[2] Jerash Univ, Fac Pharm, Jerash, Jordan
[3] Univ Hail, Coll Pharm, Dept Pharmacol & Toxicol, POB 2440, Hail, Saudi Arabia
关键词
Antiepileptic drug; Epilepsy; Insulin; Phenytoin; IMPAIRS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
INTRODUCTION: The limitations imposed by the blood-brain barrier (BBB) on the sufficient accumulation of antiepileptic drugs (AEDs) in the epileptogenic focus is considered the major cause of the high percentage of morbidity and mortality cases among epilepsy patients. This study aimed at examining the potential effect of insulin on the anticonvulsant action of phenytoin (PHT) in the mouse maximal electroshock-induced seizure model. SUBJECTS AND METHODS: PHT was administered orally in single doses either alone or in combination with insulin given as single intraperitoneal injections. To assess the anticonvulsant activity of PHT, the ED50 values were calculated. The current strength (CS50) threshold for insulin was also estimated. The animals were sacrificed, and the brains were removed to measure their PHT concentrations in the brain. RESULTS: It has been demonstrated that insulin (in all used doses) has no effect on the CS50 but can cause a significant increase in concentrations of PHT in the brain and potentiate the antiepileptic efficiency of this drug in electroshock-induced models of epilepsy in mice. CONCLUSIONS: The combination of insulin with PHT may be of great importance for developdiabetic mice.
引用
收藏
页码:8534 / 8538
页数:5
相关论文
共 23 条
  • [1] Alaraj M, 1998, ACTA NEUROBIOL EXP, V58, P283, DOI 10.55782/ane-1998-1284
  • [2] Nanotechnological Advances in the Treatment of Epilepsy
    Ali, Ola Asem Mahmoud Abdou
    Shaikh, Mohd Farooq
    Hasnain, M. Saquib
    Sami, Farheen
    Khan, Abdullah
    Ansari, Mohammed Tahir
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2022, 21 (10) : 994 - 1003
  • [3] The ABCB1, ABCC2 and RALBP1 polymorphisms are associated with carbamazepine response in epileptic patient: a systematic review
    Boughrara, Wefa
    Chentouf, Amina
    [J]. ACTA NEUROLOGICA BELGICA, 2022, 122 (04) : 871 - 880
  • [4] DANYSZ A, 1979, ARCH IMMUNOL THER EX, V27, P377
  • [5] Current Strategies for Brain Drug Delivery
    Dong, Xiaowei
    [J]. THERANOSTICS, 2018, 8 (06): : 1481 - 1493
  • [6] Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy
    Fang, Ziyan
    Chen, Shuda
    Qin, Jiaming
    Chen, Bao
    Ni, Guanzhong
    Chen, Ziyi
    Zhou, Jueqian
    Li, Ze
    Ning, Yuping
    Wu, Chuanbin
    Zhou, Liemin
    [J]. BIOMATERIALS, 2016, 97 : 110 - 121
  • [7] Neuropharmacology of Antiseizure Drugs
    Hakami, Tahir
    [J]. NEUROPSYCHOPHARMACOLOGY REPORTS, 2021, 41 (03) : 336 - 351
  • [8] Modulation of the Blood-Brain Barrier for Drug Delivery to Brain
    Han, Liang
    [J]. PHARMACEUTICS, 2021, 13 (12)
  • [9] Regulation of Tight-Junction Integrity by Insulin in an In Vitro Model of Human Blood-Brain Barrier
    Ito, Shingo
    Yanai, Mari
    Yamaguchi, Shunsuke
    Couraud, Pierre-Olivier
    Ohtsuki, Sumio
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (09) : 2599 - 2605
  • [10] Participation of Monocarboxylate Transporter 8, But Not P-Glycoprotein, in Carrier-Mediated Cerebral Elimination of Phenytoin across the Blood-Brain Barrier
    Jomura, Ryuta
    Akanuma, Shin-ichi
    Bauer, Bjorn
    Yoshida, Yukiko
    Kubo, Yoshiyuki
    Hosoya, Ken-ichi
    [J]. PHARMACEUTICAL RESEARCH, 2021, 38 (01) : 113 - 125